Anhui Huaheng Biotechnology Stock Current Valuation
| 688639 Stock | 32.21 0.15 0.47% |
Valuation analysis of Anhui Huaheng Biotec helps investors to measure Anhui Huaheng's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Anhui Huaheng's Cash is projected to increase significantly based on the last few years of reporting. The current year's Change In Cash is expected to grow to about 215.8 M, whereas Free Cash Flow is projected to grow to (919.4 M). Fundamental drivers impacting Anhui Huaheng's valuation include:
Price Book 4.3076 | Enterprise Value 9.6 B | Enterprise Value Ebitda 26.675 | Price Sales 3.8065 | Trailing PE 24.7769 |
Overvalued
Today
Please note that Anhui Huaheng's price fluctuation is not too volatile at this time. Calculation of the real value of Anhui Huaheng Biotec is based on 3 months time horizon. Increasing Anhui Huaheng's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Anhui Huaheng is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Anhui Stock. However, Anhui Huaheng's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 32.21 | Real 30.06 | Hype 31.77 | Naive 29.37 |
The real value of Anhui Stock, also known as its intrinsic value, is the underlying worth of Anhui Huaheng Biotec Company, which is reflected in its stock price. It is based on Anhui Huaheng's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Anhui Huaheng's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Anhui Huaheng Biotechnology helps investors to forecast how Anhui stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Anhui Huaheng more accurately as focusing exclusively on Anhui Huaheng's fundamentals will not take into account other important factors: Anhui Huaheng Biotechnology Company Current Valuation Analysis
Anhui Huaheng's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Anhui Huaheng Current Valuation | 9.6 B |
Most of Anhui Huaheng's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anhui Huaheng Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Anhui Huaheng Biotechnology has a Current Valuation of 9.6 B. This is 33.13% lower than that of the Biotechnology sector and 106.75% higher than that of the Health Care industry. The current valuation for all China stocks is 42.23% higher than that of the company.
Anhui Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anhui Huaheng's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Anhui Huaheng could also be used in its relative valuation, which is a method of valuing Anhui Huaheng by comparing valuation metrics of similar companies.Anhui Huaheng is currently under evaluation in current valuation category among its peers.
Anhui Fundamentals
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.0547 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 9.6 B | ||||
| Shares Outstanding | 249.72 M | ||||
| Shares Owned By Insiders | 37.82 % | ||||
| Shares Owned By Institutions | 20.72 % | ||||
| Price To Book | 4.31 X | ||||
| Price To Sales | 3.81 X | ||||
| Revenue | 1.94 B | ||||
| Gross Profit | 343.67 M | ||||
| EBITDA | 482.93 M | ||||
| Net Income | 449.06 M | ||||
| Total Debt | 941.72 M | ||||
| Book Value Per Share | 8.02 X | ||||
| Cash Flow From Operations | 301.42 M | ||||
| Earnings Per Share | 1.30 X | ||||
| Target Price | 69.07 | ||||
| Number Of Employees | 1.69 K | ||||
| Beta | 0.014 | ||||
| Market Capitalization | 8.04 B | ||||
| Total Asset | 3.97 B | ||||
| Retained Earnings | 1.05 B | ||||
| Working Capital | (626.43 M) | ||||
| Annual Yield | 0.03 % | ||||
| Net Asset | 3.97 B | ||||
| Last Dividend Paid | 0.62 |
About Anhui Huaheng Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Anhui Huaheng Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anhui Huaheng using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anhui Huaheng Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| NVDA | NVIDIA | |
| CRESY | Cresud SACIF y | |
| GOOG | Alphabet Inc Class C | |
| FMC | FMC Corporation | |
| XYF | X Financial Class |
Other Information on Investing in Anhui Stock
Anhui Huaheng financial ratios help investors to determine whether Anhui Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Anhui with respect to the benefits of owning Anhui Huaheng security.